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SaltBackground: The single-ventricle reconstruction trial randomized patients with single right ventricle lesions to
a modified Blalock-Taussig or right ventricle-to-pulmonary artery shunt at the Norwood. This analysis describes
outcomes at the stage 2 procedure and factors associated with a longer hospital length of stay (LOS).
Methods: We examined the association of shunt type with stage 2 hospital outcomes. Cox regression and
bootstrapping were used to evaluate risk factors for longer LOS. We also examined characteristics associated
with in-hospital death.
Results: There were 393 subjects in the analytic cohort. Median stage 2 procedure hospital LOS (8 days;
interquartile range [IQR], 6-14 days), hospital mortality (4.3%), transplantation (0.8%), median ventilator
time (2 days; IQR, 1-3 days), median intensive care unit LOS (4 days; IQR, 3-7 days), number of additional
cardiac procedures or complications, and serious adverse events did not differ by shunt type. Longer LOS
was associated (R2 ¼ 0.26) with center, longer post-Norwood LOS (hazard ratio [HR], 1.93 per log day;
P<.001), nonelective timing of the stage 2 procedure (HR, 1.78; P<.001), and pulmonary artery (PA) stenosis
(HR, 1.56; P<.001). By univariate analysis, nonelective stage 2 (65% vs 32%; P ¼ .009), moderate or greater
atrioventricular valve (AVV) regurgitation (75% vs 24%; P<.001), and AVV repair (53% vs 9%; P<.001)
were among the risk factors associated with in-hospital death.
Conclusions: Norwood LOS, PA stenoses, and nonelective stage 2 procedure, but not shunt type, are indepen-
dently associated with longer LOS. Nonelective stage 2 procedure, moderate or greater AVV regurgitation, and
need for AVV repair are among the risk factors for death. (J Thorac Cardiovasc Surg 2014;147:1791-8)Supplemental material is available online.
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Abbreviations and Acronyms
AVV ¼ atrioventricular valve
HLHS ¼ hypoplastic left heart syndrome
HR ¼ hazard ratio
ICU ¼ intensive care unit
IQR ¼ interquartile range
LOS ¼ length of stay
MBTS ¼ modified Blalock-Taussig shunt
PA ¼ pulmonary artery
PVR ¼ pulmonary vascular resistance
RVEDP ¼ right ventricular end-diastolic pressure
RVFAC ¼ right ventricular fractional area change
RVPAS ¼ right ventricle-to-pulmonary artery shunt
SVR ¼ single-ventricle reconstruction
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Dthere are relatively few complications.3-8 Despite the
generally excellent results, there are several preoperative
risk factors associated with prolonged LOS, hospital death,
or failure of the cavopulmonary circulation to provide
adequate oxygenation and/or acceptable hemodynamics.
The most commonly identified risks include stenosis or
distortion of the pulmonary arteries (PAs) or increased
pulmonary vascular resistance (PVR),1,9-11 atrioventricular
valve (AVV) regurgitation,10,12-14 and younger age at the
time of the stage II procedure.13,15,16
The primaryoutcome in the single-ventricle reconstruction
(SVR) trial was transplant-free survival at 12months postran-
domization between subjects with single right ventricle
anomalies palliated with a right ventricle-to-pulmonary ar-
tery shunt (RVPAS) versus a modified Blalock-Taussig shunt
(MBTS) at the Norwood procedure.17 Transplant-free sur-
vival 12 months after randomization was higher with the
RVPAS, but the trial showed several significant differences
between the 2 groups of Norwood survivors regarding
potential risk factors for the stage 2 procedure. Specifically,
PA size by angiography before the stage 2 procedure, as
measured by the Nakata index, was significantly smaller in
the RVPAS group (median, 99 [interquartile range {IQR},
63-150] vs 125 [88-166]), as was the diameter of the distal
right PA (5.2 1.7 vs 6.3 2.0mm). PA interventions during
the study period were more common in the RVPAS group
(49% vs 28%).17
The primary purpose of this analysis was to report
hospital outcomes after the stage 2 procedure in the SVR
cohort and compare these outcomes between subjects who
received the RVPAS and those who received the MBTS.
Because of the low expected mortality of the stage 2
procedure, the analyses focused predominantly on
morbidity rather than mortality. Hospital LOS was the
primary outcome, with the hypothesis that LOS would be
longer in the RVPAS group based on the increased
incidence of pulmonary artery problems previously1792 The Journal of Thoracic and Cardiovascular Surreported in this cohort. A secondary aim of this analysis
was to identify risk factors for longer LOS and in-hospital
death during the stage 2 hospitalization.METHODS
Subjects
Details of the SVR trial design have been reported.18 The Institutional
Review Board or Research Ethics Board at each participating center
approved the study protocol, and written informed consent was obtained
from parents before trial enrollment. Subjects were recruited from
15 centers in North America participating in the National Heart, Lung,
and Blood Institute–funded Pediatric Heart Network between May 2005
and July 2008. Inclusion criteria consisted of a diagnosis of HLHS or other
single right ventricle anomaly and planned Norwood procedure. Exclusion
criteria were preoperative identification of anatomy rendering either an
MBTS or RVPAS technically impossible, and any major congenital or ac-
quired extracardiac abnormality that could independently affect the likeli-
hood of the subject meeting the primary outcome of transplant-free survival
at 12 months postrandomization. Only subjects who survived to the stage 2
procedure are included in this analysis.Study Design and Measurements
Shunt type was defined for this analysis as the shunt in place at the
end of the Norwood procedure (nonintention to treat). Other than
random assignment of shunt, all participants were managed according to
the standard practices at their clinical centers.
The outcome variables for the primary analysis included hospital LOS
(primary outcome), days receiving mechanical ventilation, intensive care
unit (ICU) LOS, performance of concurrent surgical or interventional pro-
cedures at the time of the stage 2 procedure or during postoperative hospi-
talization that are not routinely part of the stage 2 operation, number of
serious adverse events and complications, and death. Those subjects who
died during the stage 2 hospitalization were excluded from the analyses
of LOS. We then analyzed potential risk factors that might influence hos-
pital LOS or in-hospital death. The factors considered in the risk factor
analysis were restricted to those judged to be clinically relevant. A full
list of candidate predictors can be found in the Table E1. For the purpose
of this analysis, unplanned postoperative procedures were limited to major
cardiovascular procedures and did not include procedures such as thora-
centesis or chest tube placement, sternal debridement, or gastrostomy
tube insertion. To examine the impact of 2 potentially important con-
founders (namely, missing data regarding PVR and subjects who were
not discharged after the Norwood and before the stage 2 procedure), alter-
native risk factor models were created.
Protocol-driven echocardiograms were obtained at a scheduled
outpatient visit before the stage 2 procedure. The echocardiograms were in-
terpreted at a core laboratory (Medical College of Wisconsin, Milwaukee)
to assess the degree of AVV regurgitation (none/mild/moderate/severe),
right ventricular end-systolic volume, right ventricular end-diastolic
volume, right ventricular fractional area change (RVFAC), and right
ventricular ejection fraction. RVFAC was the primary measurement of
right ventricular function used in further analyses. The rationale and
detailed methods for echocardiographic assessment of RV volume and
function in the SVR cohort have been detailed elsewhere.19
Cardiac catheterization was performed in most subjects before the stage
2 procedure as part of routine clinical care, and angiograms were
interpreted at a core laboratory (Duke University, Durham, NC).
Hemodynamic measurements, such as right ventricular end-diastolic
pressure (RVEDP), and calculations, such as PVR, were reported by the
enrolling center. Anatomic measurements, including PA size and stenoses,
were determined by the core laboratory. Because data needed to calculate
PVR were missing for many subjects, it was excluded from the primarygery c June 2014
FIGURE 1. Flow diagram showing the single-ventricle reconstruction
(SVR) trial cohort from inception through stage 2 hospitalization.
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Dmultivariable analysis. Total lower lobe index was calculated as a measure
of total PA size from direct measurements of the right and left lower lobe
PA diameters. This measurement has been the best measure of PA growth,
is less affected by surgery than other indexed measures of PA size,20 and
was, therefore, used as the measurement of PA size for consideration of
entry into the multivariable model.
In addition to the echocardiographic- and catheterization-based
diagnoses of AVV regurgitation and PA stenosis, we recorded the clinical
diagnoses of these conditions, which were based on the overall impression
of the treating cardiology teams.
Socioeconomic status at the time of randomization was assigned in
2 ways: (1) using a US census–based score derived from 6 measures based
on income, housing, and occupational-related features of the subject’s
census block tract21; and (2) the percentage lower than the federal poverty
level in the subject’s census block tract.
Statistical Analyses
Hospital LOS was defined by days from stage 2 procedure date (day 1)
to discharge date. Descriptive statistics are presented as mean  SD,
medians with IQR, and percentages, as appropriate. Differences between
those subjects who died versus those who survived to hospital discharge
were determined with a t test, a Wilcoxon rank-sum test, or a Fisher exact
test. A univariate Cox regression model was used to identify associations
between clinical factors and time to hospital discharge after the stage
2 procedure. Only those that were significant at P  .20 with respect to
outcome were considered for inclusion in the multivariable model. The
linearity of the covariates and the proportional hazards assumption were
evaluated both graphically and statistically. Stepwise Cox regression
selection was used in conjunction with bootstrapping (1000 samples) to
obtain reliability estimates for each of the predictors. All terms in the final
multivariable model have a P<.05 and have a reliability of greater than
50%. The primary multivariable analysis was constructed using all cases
with complete data. Two additional models were created; the first excluded
13 subjects who were not discharged between the Norwood and stage 2
operation and who have been previously described,22 and the second
included PVR from the pre–stage 2 catheterization as a potential predictor.
All analyses were conducted using SAS, version 9.2 (SAS Institute, Inc,
Cary, NC), and SAS macros for bootstrapping estimates of reliability.RESULTS
Patient Population and Diagnoses
Therewere 549 subjectswhowere randomized in the SVR
trial and underwent the Norwood procedure (Figure 1). Sub-
jects who died or were transplanted before the stage 2 proce-
dure, those with interrupted inferior vena cava resulting in a
Kawashima procedure as a second stage, those subjects with
missing data, and 1 with an uncharacteristically late stage 2
procedure at 23 months of agewere excluded from this anal-
ysis. The final cohort consisted of 393 subjects, and because
of differential rates of attrition between randomization and
the stage 2 procedure, 172 subjects had an MBTS and 221
had an RVPAS.
The cohort was 64%male and 81%white. Anatomy was
predominantly HLHS (88%). The most common associated
diagnoses before the stage 2 procedure, as reported by the
clinical teams, were branch PA stenosis (26%) and AVV
regurgitation (12%). Mean right (n ¼ 189) and left
(n ¼ 212) PA pressures at pre–stage 2 catheterization
were 14.4  3.4 and 14.7  3.8 mm Hg, respectively, andThe Journal of Thoracic and Carmean PVR (n ¼ 264) was 2.1  1.1 Wood Units 3 m2.
Pre–stage 2 angiography revealed 17% of subjects to
have 35% or greater stenosis of the left PA and 21% to
have similar stenosis of the right PA. Echocardiography
demonstrated at least moderate AVV regurgitation in 26%
and a mean RVFAC of 34%  8%. Further details can be
found in the Table E2.
Mean age at the time of the stage 2 procedure was 5.3 
1.7 months. The stage 2 procedure was elective, as reported
by the individual site investigators, in 66%. The subjects
who underwent stage 2 nonelectively were younger (4.6 
1.7 vs 5.6 1.5 months; P<.001), and the average number
of concurrent procedures was higher (1.2 1.5 vs 0.8 1.0;
P<.001). Timing of the stage 2 procedure was not associ-
ated with shunt type (29% MBTS vs 37.5% RVPAS were
nonelective; P ¼ .86). The most common reason for
nonelective timing of the stage 2 procedure was progressive
hypoxemia (n¼ 107), with ventricular dysfunction (n¼ 33),
shunt stenosis or occlusion (n¼ 17), aortic arch obstruction
(n ¼ 13), failure to thrive (n ¼ 12), AVV regurgitation
(n ¼ 12), and PA stenosis (n ¼ 5) accounting for almost
all remaining nonelective stage 2 procedures.
A right bidirectional cavopulmonary anastomosis was
the most common type of stage 2 procedure and was
performed in 64% of subjects, with a right hemi-Fontan
being the next most common at 24%. Cardiopulmonary
bypass time averaged 93  43 minutes, and 73% of cases
were performed without deep hypothermic circulatorydiovascular Surgery c Volume 147, Number 6 1793
TABLE 1. Subject and surgical characteristics at the time of stage 2 procedure
Characteristics
Overall (n ¼ 393)* Stage 2 mortality (n ¼ 17) Survivors (n ¼ 373)
P valueyMean ± SD/No. (%) Mean ± SD/No. (%) Mean ± SD/No. (%)
Age at stage 2, mo 5.3  1.7 4.9  2.2 5.3  1.6 .33
Weight-for-age z scorez 1.8  1.2 2.5  1.6 (n ¼ 15) 1.8  1.2 (n ¼ 368) .02
Timing of stage 2 procedure .009
Elective 260 (66.2) 6 (35.3) 252 (67.6)
Nonelective 133 (33.8) 11 (64.7) 121 (32.4)
Type of stage 2 procedure .65
Bidirectional cavopulmonary shunt 250 (63.6) 13 (76.5) 235 (63.0)
Hemi-Fontan 94 (23.9) 2 (11.8) 91 (24.4)
Bilateral bidirectional cavopulmonary shunts 42 (10.7) 2 (11.8) 40 (10.7)
Other 7 (1.8) 0 (0.0) 7 (1.9)
Operative support
Total CPB time, min 92.7  43.4 134.1  43.7 (n ¼ 16) 90.4  42.1 (n ¼ 371) <.001
DHCA .15
Yes 105 (26.9) 7 (43.8) 97 (26.1)
No 286 (73.1) 9 (56.3) 275 (73.9)
Concurrent proceduresx
Pulmonary artery repairs 141 (35.9) 8 (47.1) 133 (35.7) .44
Atrioventricular valve repairs 44 (11.2) 9 (52.9) 34 (9.1) <.001
Aortic arch repairs 24 (6.1) 1 (5.9) 22 (5.9) 1.00
Other vascular repairs 19 (4.8) 1 (5.9) 17 (4.6) .56
Atrial septal interventions 17 (4.3) 1 (5.9) 16 (4.3) .54
Aortic/neoaortic valve repair 9 (2.3) 0 (0.0) 9 (2.4) 1.00
ECMO 9 (2.3) 4 (23.5) 4 (1.1) <.001
EFE resection 9 (2.3) 0 9 (2.4) 1.00
Arrhythmia intervention 8 (2.0) 1 (11.8) 5 (1.3) .03
Airway procedure 5 (1.3) 0 5 (1.3) 1.00
Intervention for ICU complication 4 (1.0) 1 (5.9) 3 (0.8) .16
Atrial reduction 3 (0.8) 3 (17.7) 0 <.001
Other 7 (1.8) 1 (5.9) 6 (1.6) .27
Bold indicates P<.05. CPB, Cardiopulmonary bypass; DHCA, deep hypothermic circulatory arrest; ECMO, extracorporeal membrane oxygenation; EFE, endocardial fibroe-
lastosis; ICU, intensive care unit; SD, standard deviation. *Overall cohort includes survivors (n¼ 373), nonsurvivors (n¼ 17), and transplants before discharge (n¼ 3). yP values
obtained from t-test, Wilcoxon rank-sum test, and Fisher exact test. Test of significant differences between in-hospital deaths and survivors, but not the transplants. zFrom pre–
stage 2 echocardiogram. xIncludes postoperative procedures during stage 2 hospitalization.
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Darrest. Concurrent procedures not otherwise part of a
usual stage 2 procedure or unplanned cardiovascular
interventions before stage 2 hospital discharge were
performed in 56% of subjects. The most common
concurrent procedures were those involving PA plasty
(36%), followed by atrioventricular valve repair (11%)
and aortic arch repair (6%) (Table 1).
Stage 2 Morbidity Outcomes
Outcomes by shunt type are summarized in Table 2.
Median hospital LOS was 8 days (IQR, 6-14 days). There
were no differences in hospital LOS, ventilator days, ICU
LOS, number of concurrent procedures, serious adverse
events, or complications between subjects with an RVPAS
and those with an MBTS.
Univariate Analysis for LOS
The analysis for the primary outcomewas performed on a
cohort of 372 subjects, which excluded 17 in-hospital
deaths, 3 in-hospital heart transplants, and 1 subject with1794 The Journal of Thoracic and Cardiovascular Surno information regarding discharge in the data set. The
list of candidate predictors for hospital LOS after the stage
2 procedure and the univariate modeling results can be
found in the Table E2.
Multivariable Model for LOS
Longer hospital LOS was independently associated
(R2¼ 0.26) with center, longer post-Norwood LOS (hazard
ratio [HR], 1.93 per log day; P<.001), nonelective timing
for the stage 2 procedure (HR, 1.78; P<.001), and a clinical
diagnosis of branch PA stenosis at the time of the stage 2
procedure (HR, 1.56; P<.001) (Table 3). Shunt type was
not significant when added to this model (P ¼ .92). An
alternative analysis that excluded the 13 subjects who
were not discharged from the hospital after the Norwood
procedure showed the same associations as the primary
model and an additional inverse association between
RVFAC and post–stage II LOS (Table 4). A multivariable
model (N ¼ 253) that excluded subjects in whom PVR
could not be measured found the same significant riskgery c June 2014
TABLE 2. Outcomes by shunt type*
Overall (N ¼ 393) MBTS (n ¼ 172) RVPAS (n ¼ 221)
P valueyMean ± SD/No. (%)
Median
(IQR) Mean ± SD/No. (%)
Median
(IQR) Mean ± SD/No. (%)
Median
(IQR)
No. of in-hospital deaths 17 (4.3) 7 (4.1) 10 (4.5) 1.00
No. of in-hospital transplants 3 (0.8) 1 (0.6) 2 (0.9) 1.00
Length of hospital stay, dz 13.9  17.0 8 (6-13) 12.5  13.9 8 (6-11.5) 15.0  19.1 8 (6-15.0) .07
Total ventilated time, dz 4.0  12.3 2 (1-3) 3.1  5.7 2 (1-3) 4.8  15.7 2 (1-3.5) .34
Total ICU time, dz 8.0  14.3 4 (3-7) 7.2  10.8 4 (3-6) 8.6  16.6 4 (3-8) .11
No. of SAEs or complications 1.2  2.5 0 (0-1) 1.1  1.8 0 (0-2) 1.3  3.0 0 (0-1) .84
0 210 (53.4) 91 (52.9) 119 (53.8) .96
1 85 (21.6) 37 (21.5) 48 (21.7)
2 98 (24.9) 44 (25.6) 54 (24.4)
No. of concurrent proceduresx 0.9  1.2 1 (0-1) 0.9  1.1 1 (0-1) 0.9  1.3 1 (0-1) .77
0 174 (44.3) 76 (44.2) 98 (44.3) .58
1 147 (37.4) 68 (39.5) 79 (35.8)
2 72 (18.3) 28 (16.3) 44 (19.9)
MBTS, Modified Blalock-Taussig shunt; RVPAS, right ventricle-to-pulmonary artery shunt; IQR, interquartile range; ICU, intensive care unit; SAE, serious adverse event;
SD, standard deviation. *Refers to shunt type in place at the end of the Norwood procedure. yP values obtained from Wilcoxon rank-sum test and Fisher exact test. zExcluding
deaths and transplants. xIncludes postoperative procedures during stage 2 hospitalization.
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Dfactors as the primary model, except that higher PVR (HR,
1.24 per 1 Wood Unit 3 M2; P ¼ .004), instead of
pulmonary artery stenosis, was associated with longer
hospital LOS (Table 5). The incidence of 35% or greater
branch stenosis was similar between those subjects with
PVR reported and those for whom those data were missing
(data not shown). Median hospital LOS was calculated for
subgroups defined by the presence versus absence of all
possible combinations of the 3 risk factors identified in
the multivariable model (Table 6). A cut point of 24 days
was used to define prolonged LOS after the Norwood oper-
ation, because this was the median LOS for transplant-free
survivors who later underwent a stage 2 procedure. The
median LOS after the stage 2 procedure was 6 days when
no risk factors were present and 13 days when all 3 risk
factors were present.TABLE 4. Final model for risk factors associated with stage 2 hospital
length of stay excluding 13 subjects not discharged between Norwood
and stage 2 procedures (N ¼ 331, generalized R2 ¼ 0.24)
Hazard ratio Reliability,Mortality
Seventeen subjects (4%) died after the stage 2
procedure and before hospital discharge. An additional 3TABLE 3. Final model for risk factors associated with stage 2 hospital
length of stay (N ¼ 371, generalized R2 ¼ 0.26)
Variable
Hazard ratio
(95% CI) P value
Reliability,
%
Site .002 97
Log of Norwood length of
stay, d
1.93 (1.60-2.34) <.001 99
Nonelective reason for timing
of stage 2
1.78 (1.38-2.31) <.001 78
Associated clinical diagnosis
with stage 2: branch PA
stenosis present
1.56 (1.20-2.02) <.001 64
Bold indicates P<.05. CI, Confidence interval; PA, pulmonary artery.
The Journal of Thoracic and Carsubjects (1%) remained in the hospital until transplantation.
Univariate comparison of those subjects who died or were
transplanted during the stage 2 hospitalization with those
subjects who survived to discharge without transplant
is shown in Table 1. Characteristics associated with in-
hospital mortality or transplantation included longer
Norwood LOS, not being discharged between the Norwood
and stage 2 procedures, extracorporeal membrane oxygen-
ation after the Norwood, nonelective timing of the stage 2
procedure, a clinical diagnosis of AVV regurgitation
at the time of the stage 2 procedure, higher RVEDP at
pre–stage 2 catheterization, lower weight-for-age z score
at the time of the pre–stage 2 echocardiogram, moderate
or greater AVV regurgitation on pre–stage 2 echocardio-
gram, longer total cardiopulmonary bypass time at the stageVariable (95% CI) P value %
Site <.001 98
Log of Norwood length of
stay, d
1.56 (1.25-1.96) <.001 79
Nonelective reason for
timing of stage 2
1.88 (1.42-2.50) <.001 89
Associated clinical diagnosis
with stage 2: branch PA
stenosis present
1.60 (1.22-2.10) <.001 81
Pre–stage 2 echo: RV
fractional area change
(range, 0-1)*
0.91 (0.85-0.98)
per 0.05 increase
.017 54
Bold indicates P< .05. CI, Confidence interval; PA, pulmonary artery; RV, right
ventricle. *Twenty-eight subjects had missing RV fractional area change on pre–stage
2 echo.
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TABLE 5. Final model for risk factors associated with stage 2 hospital
length of stay including only subjects for whom PVR calculations were
available (N ¼ 253, generalized R2 ¼ 0.28)
Variable
Hazard ratio
(95% CI) P value
Reliability,
%
Site .003 95
Log of Norwood length
of stay, d
1.84 (1.48-2.30) <.001 99
Nonelective reason for
timing of stage 2
1.51 (1.09-2.09) .013 62
Pre–stage 2 catheterization
PVR, Wood units
1.24 (1.07-1.44) .004 69
Bold indicates P<.05. PVR, Pulmonary vascular resistance; CI, confidence interval.
Congenital Heart Disease Schwartz et al
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D2 procedure, and surgical atrioventricular valve repair
during the stage 2 hospitalization. Among those with elec-
tive timing of the stage 2 procedure, there was no
statistically significant relationship between age at the stage
2 procedure and death or transplant (data not shown).
Because of the overall low in-hospital mortality/transplant
rate, multivariable modeling was not performed.DISCUSSION
Outcomes of stage 2 hospitalization for subjects enrolled
in the Pediatric Heart Network–sponsored SVR trial were
favorable and not associated with the type of shunt placed
at the initial Norwood procedure. The median hospital
LOS was 8 days, consistent with several previous single-
center reports,5-8,12,23-25 although some series have
reported considerably longer LOS, ranging from 11 to 21
days.13,26 Given this wide variability in LOS in the
published literature, it is not surprising that there was a
significant association of LOS with the surgical center at
which the stage 2 procedure was performed.
Both anatomic and physiologic PA complications have
been implicated as risk factors for worse stage 2 outcomes,
including pulmonary vascular resistance of greater than 3
Wood Units 3 M2 and PA distortion,1 although others
have reported that PA augmentation does not increase
mortality risk.2 More contemporary series suggest a greater
adverse consequence of elevated PVR than PA stenosis, atTABLE 6. Median stage 2 procedure LOS (days) by risk factor group
No. of risk
factors
Norwood
LOS>24 d
Reason for
timing of stage
2 procedure
Diagnosis
of PA
stenosis
Median stage
2 procedure
LOS
0 (Best) No Elective No 6 (n ¼ 91)
1 Yes Elective No 8 (n ¼ 97)
1 No Nonelective No 8 (n ¼ 38)
1 No Elective Yes 8 (n ¼ 36)
2 Yes Elective Yes 9 (n ¼ 27)
2 No Nonelective Yes 9 (n ¼ 18)
2 Yes Nonelective No 14 (n ¼ 48)
3 (Worst) Yes Nonelective Yes 13 (n ¼ 16)
LOS, Length of stay (days); PA, pulmonary artery.
1796 The Journal of Thoracic and Cardiovascular Surleast with respect to mortality before the Fontan opera-
tion.9,11,27 Regarding hospital LOS, Gray and colleagues26
found that the need to place a stent in the RVPAS before
the stage 2 procedure was associated with a 10-day increase
in LOS. The current study found that a clinical diagnosis of
branch PA stenosis was the measurement most associated
with increased hospital LOS, even more so than detailed
angiographic measurements. This model did not include
PVR because this measurement was obtained in only 253
of the 393 subjects in the cohort. When PVR was included
in the model, branch PA stenosis was no longer associated
with increased hospital LOS. PVR cannot be easily
measured in subjects with significant branch PA stenosis,
and it is, therefore, likely that the latter model excluded
most subjects with significant branch PA stenosis. Further-
more, measures of total PA growth (Nakata index or the
lower lobe index) were not associated with stage 2 mortality
in a univariate analysis.
We hypothesized that the RVPAS group would have a
longer hospital LOS because of smaller PA size and
increased number of PA interventions between the
Norwood and stage 2 procedures. Hospital LOS after the
stage 2 procedure tended to be longer in the RVPAS group,
although this did not reach statistical significance (mean,
15.0 vs 12.5 days; identical medians, 8 days; Wilcoxon
P ¼ .07 and Cox model for time to discharge P ¼ .14).
Therefore, it appears that it is really pulmonary artery
anatomy rather than shunt type that is associated with stage
2 outcomes. Smaller series have shown no difference
between the RVPAS and MBTS on outcomes at the stage 2
procedure,23,24 and Januszewska and colleagues28 reported
a shorter ICU LOS with the RVPAS compared with the
MBTS. Although our data suggest that it is PA abnorma-
lities, rather than shunt type alone, that are associated
with longer LOS, the RVPAS seems likely to be responsible
for more PA abnormalities than the MBTS.
The finding that LOS after the stage 2 procedure is
associated with a longer LOS after the Norwood
procedure likely represents a surrogate for a multitude of
other problems, such as ongoing heart failure from dimin-
ished ventricular function or AVV regurgitation, feeding
difficulties, or other complications that result in morbidity.
All of these variables were significantly associated with
prolonged stage 2 hospital LOS in the univariate, but not
the multivariable, analysis. Friedman and colleagues14
found that prolonged LOS after the Norwood procedure
was associated with failure to complete the Fontan
procedure, suggesting that these complications have long-
term consequences in this population.
Similarly, the association of nonelective timing of the
stage 2 procedure with longer stage 2 hospital LOS may
reflect several anatomic and physiologic complications.
Although age at procedure and weight z-score were
univariate predictors of LOS in the current study, theygery c June 2014
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supported by the observations that subjects who underwent
nonelective stage 2 were younger and more likely to have
concurrent procedures. Several previous investigators
have shown associations between younger age or
smaller size and complications resulting in prolonged
LOS8,15,24,29 or death16 after the stage 2 procedure. A
comparison of those undergoing the stage 2 procedure at
younger than 3months of agewith thosewhowere 3months
or older did not identify an independent effect of age when
other factors, such as preoperative PA pressure and AVV
regurgitation, were taken into account.10
The stage 2 procedure in-hospital mortality rate in this
multicenter cohort was 4%, with an additional 1% of sub-
jects undergoing heart transplantation before discharge.
Most reports from single centers have indicated mortality
rates of less than 2%, and frequently less than
1%.4-7,12,25,28 Even those series limited to patients with
HLHS6,28 and, thus, anatomically similar to the current
cohort have generally, although not universally,11 demon-
strated lower hospital mortality than in the SVR cohort, and
Scheurer and colleagues12 found that HLHS was not associ-
ated with any additional risk at the stage 2 procedure in a se-
ries of single-ventricle patients. An important difference
between the SVR trial cohort and others is that the SVR
cohort is an incident cohort and might, therefore, be more in-
clusive than single-center reports. Also, publication bias may
favor lower mortality rates being published.
Several factors were associated with mortality in a
univariate analysis. Of particular note is moderate or greater
AVV regurgitation, whether noted on the pre–stage 2
echocardiogram or as a clinical diagnosis, AVV repair
concurrent with the stage 2 procedure, and an increased
RVEDP at the pre–stage 2 catheterization. AVV regurgita-
tion has been identified as a risk for early10 and late12-14
mortality after the stage 2 procedure. Hypoplastic left
heart syndrome patients with AVV regurgitation may be
at higher risk than those with other types of single-
ventricle anatomy,29 although there are also reports that
AVV regurgitation is not associated with in-hospital
mortality at the stage 22 or Fontan procedures,30 unlike
the current results. Longer-term follow-up of the subjects
in the SVR cohort who have undergone AVV repair will
be important to determine if the strategy attempting repair
of the moderate or severely regurgitant AVV at the time of
the stage 2 procedure is ultimately successful.
There are several limitations to our investigation. Practice
variation exists between centers, as was reflected by the sig-
nificant association of center with hospital LOS. Further-
more, our multivariable model accounted for only 26% of
thevariance inLOS, suggesting that there are other important
issues that affect individual patients and were not measured
or analyzed herein despite the extensive nature of the SVR
database. As previously discussed, many variables evaluatedThe Journal of Thoracic and Carin this study may be confounded with others, such as age at
stage 2 and nonelective timing for stage 2. Consequently,
some variables deemed important in the multivariable
models may only be surrogates for other unmeasured vari-
ables. By adjusting for site and using bootstrapping, we
have tried to minimize bias and maximize reliability.
In conclusion, we found that the stage 2 procedure for
HLHS and other single right ventricle anomalies is most
commonly followed by a relatively short hospital course
with a few clinically significant complications, and this is
unrelated to the shunt type placed at the Norwood opera-
tion. Overall hospital mortality after the stage 2 procedure
is low in this generally high-risk population, although the
need for additional surgical and interventional procedures
at the time of the stage 2 hospitalization is relatively high.
Patients who require a nonelective stage 2 procedure, those
with a diagnosis of branch PA stenosis, and those who had a
prolonged LOS after the Norwood procedure are at
significant risk for a prolonged hospital LOS after the stage
2 procedure.References
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TABLE E1. Cox regression model for predictors of length of hospital
stay
Variable No.
Hazard ratio
(95% CI) P value
Center 372 .004
Demographics
Sex
Male 238 1.05 (0.85-1.30) .62
Female 135 Reference
Hispanic
Yes 69 1.27 (0.97-1.65) .08
No 300 Reference
Race .27
White 304 Reference
Black 51 0.79 (0.59-1.06)
Other 14 1.09 (0.63-1.88)
SES score 360 0.98 (0.96-1.00) .09
Genetic syndrome .02
Yes 91 Reference
No 196 0.79 (0.59-1.06)
Unknown 85 1.09 (0.63-1.88)
Anatomy
HLHS .88
Yes 333 1.03 (0.74-1.43)
No 40 Reference
Clinical diagnoses at time
of stage 2 procedure
Branch PA stenosis .16
Yes 97 1.18 (0.94-1.49)
No 274 Reference
AVVR .003
Yes 37 1.69 (1.20-2.39)
No 334 Reference
Aortic arch obstruction .53
Yes 28 1.13 (0.77-1.67)
No 343 Reference
Norwood hospitalization
Shunt type at the end of
Norwood
.14
MBTS 164 Reference
RVPAS 208 1.17 (0.95-1.44)
Log-transformed
Norwood LOS
372 1.80 (1.53-2.13) <.001
Discharge after
Norwood
operation
<.001
No 13 4.13 (2.29-7.44)
Yes 359 Reference
On ECMO .03
Yes 25 1.64 (1.07-2.52)
No 348 Reference
Interstage interventions
ECMO
Yes 5 1.42 (0.58-3.43) .44
No 368 Reference
(Continued)
TABLE E1. Continued
Variable No.
Hazard ratio
(95% CI) P value
Interstage intervention
on aorta
.543
Yes 62 1.09 (0.83-1.43)
No 310 Reference
Interstage intervention
on PA
.95
Yes 10 1.02 (0.54-1.91)
No 362 Reference
Interstage intervention
on atrial septum
.66
Yes 10 0.87 (0.46-1.63)
No 362 Reference
Other interstage
intervention
.89
Yes 31 1.03 (0.71-1.48)
No 341 Reference
Pre–stage 2
cathetherization/
echocardiogram
RVFAC (range, 0-1) 344 0.93 (0.87-1.003) per
0.05-unit increase
.06
Moderate tricuspid
valve regurgitation
365
Yes 86 1.52 (1.19-1.95) .001
No 279 Reference
Pre–stage 2
catheterization
hemodynamics
Ventricular
end-diastolic
pressure from
cathetherization, mm
Hg
348 1.03 (1.00-1.06) .08
Pulmonary vascular
resistance, Wood
units
253 1.21 (1.07-1.35) .001
Pre–stage 2 angiography
Severity of LPA
stenosis,%
325 1.00 (0.99-1.00) .64
<15 196 1.16 (0.72-1.89) .73
15-<35 75 1.04 (0.62-1.74)
35-<50 36 1.25 (0.71-2.21)
50 18 Reference
Severity of RPA
stenosis,%
325 1.16 (0.72-1.89) .13
<15 175 1.04 (0.62-1.74) .21
15-<35 80 1.25 (0.71-2.21)
35-<50 40 1.16 (0.72-1.89)
50 30 Reference
Total lower lobe index,
mm2/M2*
322 0.94 (0.89-0.989) per a
50-unit increase
.02
Nakata index 322 0.96 (0.90-1.03) per a
50-unit increase
.27
(Continued)
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TABLE E1. Continued
Variable No.
Hazard ratio
(95% CI) P value
At stage 2
Reasons for timing of
stage 2 procedure
<.001
Elective 252 0.61 (0.49-0.77)
Nonelective 120 Reference
Age at stage 2 0.96 (0.90-1.01) .11
Weight-age z score on
pre–stage 2 echo
368 0.89 (0.81-0.97) .009
Type of stage 2 .81
Bidirectional
cavopulmonary
shunt
234 0.85 (0.40-1.80)
Hemi-Fontan 91 0.84 (0.39-1.81)
Bidirectional
cavopulmonary
anastomoses
40 0.73 (0.33-1.64)
Other 7 Reference
Total CPB time, per
10-min increase
370 1.05 (1.02-1.08) <.001
On DHCA 371 .56
Yes 1.07 (0.85-1.35)
No Reference
Concurrent procedures:
PA repair
372 .01
Yes 133 1.32 (1.06-1.63)
No 239 Reference
Concurrent procedures:
aortic arch repair
372 .09
Yes (n ¼ 22) 22 1.46 (0.95-2.25)
No (n ¼ 350) 350 Reference
Concurrent procedures:
AV valve repair
372 .03
Yes 34 1.49 (1.04-2.12)
No 338 Reference
Concurrent procedures:
aortic valve repair
372 .48
Yes 9 0.79 (0.41-1.53)
No 363 Reference
Concurrent: ASD 372 .73
Yes 16 0.92 (0.55-1.51)
No 356 Reference
Bold indicates P<.05. CI, Confidence interval; SES, socioeconomic status; HLHS,
hypoplastic left heart syndrome; PA, pulmonary artery; AVVR, atrioventricular valve
regurgitation; MBTS, modified Blalock-Taussig shunt; RVPAS, right ventricle-to-
pulmonary artery shunt; LOS, length of hospital stay; ECMO, extracorporeal
membrane oxygenation; RVFAC, right ventricle fractional area change; LPA, left
pulmonary artery; RPA, right pulmonary artery; CPB, cardiopulmonary bypass;
DHCA, deep hypothermic circulatory arrest; AV, atrioventricular; ASD, atrial septal
defect. *Total lower lobe index was defined as follows: 3.143 (right lower lobe diam-
eter/2)2 þ 3.14 3 ([left lower lobe diameter/2]2)/body surface area.
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TABLE E2. Characteristics of the analytic cohort of subjects undergoing the stage 2 procedure
Characteristics
Overall (N ¼ 393)* Stage 2 mortality (n ¼ 17)
Nontransplant
survivors (n ¼ 373)
P valueyMean ± SD/No. (%) Mean ± SD/No. (%) Mean ± SD/No. (%)
Demographics
Male 250 (63.6) 11 (64.7) 238 (63.8) 1.00
Hispanic .32
Yes 70 (18.1) 1 (6.7) 69 (18.7)
No 317 (81.9) 14 (93.3) 300 (81.3)
Unknown 6 2 4
Race .10
White 317 (81.3) 11 (64.7) 304 (82.2)
Black 58 (14.9) 5 (29.4) 52 (14.1)
Other 15 (3.9) 1 (5.9) 14 (3.8)
Unknown 3 0 3
SES score 0.4  5.1 0.4  3.6 0.4  5.1 .97
Genetic syndrome/other anomalies .005
Yes 93 (23.7) 1 (5.9) 91 (24.4)
No 204 (51.9) 6 (35.3) 196 (52.5)
Unknown 96 (24.4) 10 (58.8) 86 (23.1)
Anatomy
HLHS 346 (88.0) 11 (64.7) 333 (89.3) .009
Clinical diagnoses at time of stage 2 procedurez
Branch PA stenosis present 102 (26.1) 4 (25.0) 98 (26.3) 1.00
AVVR 45 (11.5) 8 (50.0) 37 (10.0) <.001
Aortic arch obstruction 30 (7.7) 1 (6.3) 28 (7.5) 1.00
Norwood hospitalization
Shunt type at the end of Norwood 1.00
MBTS 172 (43.8) 7 (41.2) 164 (44.0)
RVPAS 221 (56.2) 10 (58.8) 209 (56.0)
Length of Norwood hospitalization, d 33.8  30.8; median
(IQR), 24 (17-39)
72.2  51.7;
median, 61
31.928.3; median, 24 <.001
Not discharged after Norwood 22 (5.6) 8 (47.1) 13 (3.5) <.001
ECMO during Norwood hospitalization 32 (8.1) 6 (35.3) 25 (6.7) .001
Interstage interventions
ECMO 5 (1.3) 0 5 (1.3) 1.00
Intervention on aorta 68 (17.3) 4 (23.5) 63 (16.9) .51
Intervention on PA 10 (2.5) 0 (0.0) 10 (2.7) 1.00
Intervention on atrial septum 10 (2.5) 0 (0.0) 10 (2.7) 1.00
Other interventions 32 (8.1) 1 (5.9) 31 (8.3) 1.00
Pre–stage 2 echocardiography
RVFAC 0.34  0.08 (n ¼ 363) 0.31  0.06 (n ¼ 16) 0.34  0.08 (n ¼ 344) .17
Moderate tricuspid valve regurgitation <.001
Yes 100 (26.0) 12 (75.0) 86 (23.6)
No 284 (74.0) 4 (25.0) 279 (76.4)
Catheterization hemodynamics
RVEDP, mm Hg 8.3  3.3 (n ¼ 366) 10.8  3.5 (n ¼ 16) 8.1  3.2 (n ¼ 348) .001
PVR, Woods units 2.1  1.1 (n ¼ 264) 1.9  0.7 (n ¼ 10) 2.1  1.2 (n ¼ 253) .61
Transpulmonary gradient, mm Hg 4.9  3.1 (n ¼ 159) 5.2  2.4 (n ¼ 7) 4.8  3.1 (n ¼ 150) .76
Angiography
LPA stenosis at site of maximal stenosis
(relative to proximal left lower diameter),%
14.4  18.9 (n ¼ 336);
median (IQR),
2.0 (0.0-26.5)
18.2  21.9 (n ¼ 11) 14.3  18.8 (n ¼ 325) .50
<15 202 (60.1) 6 (54.5) 196 (60.3) .62
15-35 77 (22.9) 2 (18.2) 75 (23.1)
35-50 38 (11.3) 2 (18.2) 36 (11.1)
>50 19 (5.7) 1 (9.1) 18 (5.5)
(Continued)
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TABLE E2. Continued
Characteristics
Overall (N ¼ 393)* Stage 2 mortality (n ¼ 17)
Nontransplant
survivors (n ¼ 373)
P valueyMean ± SD/No. (%) Mean ± SD/No. (%) Mean ± SD/No. (%)
RPA stenosis at site of maximal stenosis (relative
to proximal right lower diameter),%
18.2  20.6 (n ¼ 337);
median (IQR),
10.0 (0.0-33.0)
22.0  19.1 (n ¼ 11) 18.1  20.6 (n ¼ 325) .54
<15 180 (53.4) 4 (36.4) 175 (53.8) .45
15-35 85 (25.2) 5 (45.5) 80 (24.6)
35-50 41 (12.2) 1 (9.1) 40 (12.3)
>50 31 (9.2) 1 (9.1) 30 (9.2)
Total lower lobe index, mm2/M2x 167.0  90.0 (n ¼ 333) 169.5  72.2 (n¼11) 167.0  90.6 (n ¼ 322) .93
Nakata index 128.5  81.0 (n ¼ 333) 114.3  53.7 (n ¼ 11) 129.0  81.8 (n ¼ 322) .56
Bold indicates P<.05. SES, Socioeconomic status; HLHS, hypoplastic left heart syndrome; PA, pulmonary artery; AVVR, atrioventricular valve regurgitation; MBTS, modified
Blalock-Taussig shunt; RVPAS, right ventricle-to-pulmonary artery shunt; IQR, interquartile range; ECMO, extracorporeal membrane oxygenation; RVFAC, right ventricular
fractional area change; RVEDP, right ventricular end-diastolic pressure; PVR, pulmonary vascular resistance; LPA, left pulmonary artery; RPA, right pulmonary artery; SD, stan-
dard deviation. *Overall cohort includes survivors (n¼ 373), nonsurvivors (n¼ 17), and transplants before discharge (n¼ 3). yP values obtained from t-test, Wilcoxon rank-sum
test, and Fisher exact test. Test of significant differences between in-hospital deaths and survivors, but not the transplants. zAs designated by overall clinical evaluation. xTotal
lower lobe index was defined as follows: 3.14 3 (right lower lobe diameter/2)2 þ 3.14 3 [(left lower lobe diameter/2)2]/body surface area.
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